Reinitiating obesity meds after bariatric surgery tied to greater one-year weight loss in youths
A study published in JAMA Surgery indicates that reinitiating obesity medications shortly after sleeve gastrectomy leads to significantly higher weight loss in adolescents compared to surgery alone. The research found improved BMI reduction and better eating behaviors without an increase in postoperative complications.
Why it matters
This finding suggests a more effective clinical protocol for managing adolescent obesity, potentially improving long-term health outcomes for post-bariatric patients.
edited by Gaby Clark , reviewed by Alexander Pol
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Restarting obesity medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, soon after sleeve gastrectomy (SG) is associated with greater one-year weight loss than surgery alone in adolescents, according to a research letter published online July 22 in JAMA Surgery .
Dr. Alaina P. Vidmar, from Children's Hospital Los Angeles, and colleagues evaluated the 12-month safety, weight trajectory and eating behavior outcomes associated with early reinitiation of obesity medications following metabolic and bariatric surgery. The analysis included 99 youths ages 7–20 who underwent SG between November 2023 and February 2026.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in